Sai Life Sciences completes Phase II of production block 11 at Bidar
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
This strategic investment strengthens Cohance's integrated oligonucleotide platform
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
Subscribe To Our Newsletter & Stay Updated